Emergent BioSolutions

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

Emergent BioSolutions Inc.
Company typePublic company
Traded as
  • NYSE: EBS
  • Russell 2000 component
FoundedSeptember 5, 1998 (1998-09-05) (as BioPort Inc.)
FounderFuad El-Hibri
HeadquartersGaithersburg, Maryland, U.S.
Key people
Haywood Miller (interim CEO)
Zsolt Harsanyi (Chairman)
RevenueUS$1.793 billion (2021)
US$352.6 million (2021)
Net income
US$230.9 million (2021)
Number of employees
2,416 (December 31, 2021)
Websitewww.emergentbiosolutions.com

Among the company's products are the controversial BioThrax (Anthrax Vaccine Adsorbed), the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.

During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.